Higher cardiorespiratory fitness (CRF) is associated with a lower risk for incident lung and colorectal cancer and with a lower risk for all-cause mortality among those diagnosed with lung and colorectal cancer.
The median number of prior treatments for patients with relapsed colorectal cancer enrolled in this phase 2 study was 6.
The companion study arms under the COLOMATE trial umbrella will include those that specifically enroll patients with HER2-amplified or EGFR-mutant disease.
The appearance of structural variants in MACROD2, culled from sequencing data from patients with colorectal cancer, may be a hallmark of CRC pathogenesis.
Most patients with HER2-amplified colorectal cancer who achieved a response to pertuzumab plus trastuzumab had disease characterized as KRAS wild-type.
Reductions in the risk of cancer were more pronounced in men and younger patients with vitiligo.
Higher circulating levels of 25(OH)D were also inversely associated with BRAF V600E-mutant colorectal cancer.
Some patients with colorectal cancer are more likely to have disease characterized by a high frequency of mutations, microsatellite instability, and strong immune activation.
This study was presented at the 2019 International Congress on Targeted Anticancer Therapies (TAT) in Paris, France, from February 25-27, 2019. Dr Jun Sato of the National Cancer Center Hospital, Japan is the lead author of this study.1 Results from a retrospective study evaluating the focus of early-phase clinical trials of investigational drug candidates in…
Obesity in childhood and adolescence may be related to the disproportionate rise in certain obesity-related cancers in younger adults, according to authors.
